Bonus Biogroup is developing investigational cell therapy and tissue engineering solutions to address conditions involving tissue damage, bone loss, and inflammation. Our proprietary technology platform supports the clinical development of BonoFill and MesenCure, which are currently undergoing evaluation in clinical studies. BonoFill is being investigated as a patient-specific viable bone graft for maxillofacial, dental, and orthopedic applications. MesenCure is being studied as an allogeneic cell therapy for respiratory distress and other inflammatory conditions. Additional research is ongoing to explore new therapeutic indications.